Related Experiment Videos
Waldenström's macroglobulinemia associated with AA amyloidosis
1Hematology Unit, Rabin Medical Center, Petah-Tikva, Israel.
Abstract:
It is widely accepted that amyloidosis in Waldenström's macroglobulinemia (WM) is exclusively due to amyloid light-chain deposition. However, only a small number of previous reports have actually characterized the type of amyloid in WM. We now report the third patient with WM and amyloid A protein (AA) amyloidosis. This patient developed malabsorption, nephrotic syndrome, and orthostatic hypotension. AA was immunohistochemically demonstrated in the rectal biopsy. In conjunction with previous examples of AA amyloidosis, the present report raises the possibility that AA amyloidosis may also occur in WM patients.
Insights
Amyloid A protein (AA) amyloidosis is rarely seen in Waldenström's macroglobulinemia (WM). This case report suggests AA amyloidosis may occur in WM patients, challenging the exclusive light-chain deposition theory.
Area of Science:
- Hematology
- Oncology
- Nephrology
Background:
- Waldenström's macroglobulinemia (WM) is a rare lymphoproliferative disorder.
- Amyloidosis in WM is typically attributed to amyloid light-chain (AL) deposition.
- Previous characterization of amyloid types in WM is limited.
Observation:
- A patient with WM presented with malabsorption, nephrotic syndrome, and orthostatic hypotension.
- Immunohistochemical analysis of a rectal biopsy confirmed amyloid A protein (AA) deposition.
- This represents the third reported case of AA amyloidosis in a patient with WM.
Findings:
- The study presents a case of Waldenström's macroglobulinemia associated with amyloid A protein (AA) amyloidosis.
- This finding challenges the long-held belief that only amyloid light-chain (AL) deposition causes amyloidosis in WM.
- The presence of AA amyloidosis in this WM patient is supported by immunohistochemical evidence.
Implications:
- The findings suggest that AA amyloidosis should be considered in the differential diagnosis of amyloidosis in WM patients.
- This broadens the understanding of potential amyloidogenic pathways in WM.
- Further investigation is warranted to determine the frequency and clinical significance of AA amyloidosis in WM.